# Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

> **NCT07339839** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 42 (estimated)

## Conditions studied

- NSCLC Stage IV
- KRAS G12C

## Interventions

- **DRUG:** Glecirasib
- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT07339839
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339839, "Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT07339839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*